EP0120328A2 - Pharmazeutische Zusammensetzung welche 5-Acetamido-3,5-Dideoxy-D-Glycero-D-Galactononulosaminsäure Cytidin Monophosphat enthält - Google Patents

Pharmazeutische Zusammensetzung welche 5-Acetamido-3,5-Dideoxy-D-Glycero-D-Galactononulosaminsäure Cytidin Monophosphat enthält Download PDF

Info

Publication number
EP0120328A2
EP0120328A2 EP84102059A EP84102059A EP0120328A2 EP 0120328 A2 EP0120328 A2 EP 0120328A2 EP 84102059 A EP84102059 A EP 84102059A EP 84102059 A EP84102059 A EP 84102059A EP 0120328 A2 EP0120328 A2 EP 0120328A2
Authority
EP
European Patent Office
Prior art keywords
acid
nana
cmp
enzyme
condensation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP84102059A
Other languages
English (en)
French (fr)
Other versions
EP0120328A3 (en
EP0120328B1 (de
Inventor
Enio Dr. Decorte
Pietro Dr. Miccoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crc Di Ricerca Chimica SpA Cia
CRC Compagnie di Ricerca Chimica SpA
Original Assignee
Crc Di Ricerca Chimica SpA Cia
CRC Compagnie di Ricerca Chimica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT83341/83A external-priority patent/IT1175061B/it
Priority claimed from IT83371/83A external-priority patent/IT1175084B/it
Application filed by Crc Di Ricerca Chimica SpA Cia, CRC Compagnie di Ricerca Chimica SpA filed Critical Crc Di Ricerca Chimica SpA Cia
Priority to AT84102059T priority Critical patent/ATE37984T1/de
Publication of EP0120328A2 publication Critical patent/EP0120328A2/de
Publication of EP0120328A3 publication Critical patent/EP0120328A3/en
Application granted granted Critical
Publication of EP0120328B1 publication Critical patent/EP0120328B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/305—Pyrimidine nucleotides

Definitions

  • the present invention relates to pharmaceutical compositions for use in the therapy of pathological states related to disturbances of the nervous stimulus in the central (CNS) and peripheral (PNS) nervous system containing as an active substance the cytidine monophosphate of 5-acetamido-3,5-dideoxy-D-glycero-D-galactononulosaminic acid. Moreover the invention relates to an improved method for preparing said compound.
  • CMP-NANA 5-acetamido-3,5-dideoxy-5-glycero-D-galactononulosaminic acid
  • CMP-NeuAc CMP-NeuAc
  • NANA N-acetyl-neuraminic acid
  • NANA represents the physiologically active part of the molecules found in the membranes (gangliosides and glycoproteins), that are generally structured in the way to be able to receive and to transmit all necessary informations for the functioning of the cell (see e.g. R.W. Jeanloz et al. The Biological Role of Sialic Acid at the Surface of the Cell, in Biological Roles of Sialic Acid, A. Rosenberg et al.Eds., Plenum Press, pp 201-227, 1976).
  • CMP-NANA represents the physiological substrate of the enzyme sialyl transferase, that consents its incorporation into the already indicated subunits of the biological membrane, i.e. gangliosides and glycoproteins.
  • NANA NANA imparts to the surface of the membrane, which modulates its functional activity.
  • R. Jbernacki et al. The Glycoconjugates vol. IV part B, M.I. Horowitz E., Academic Press, pp. 256-261, 1982; S. Ng et al., The Natural Occurence of Sialic Acid, in Biological Roles of Sialic Acid, A. Rosenberg et al., Eds, Plenum Press, pp. 59-86, 1976).
  • CMP-NANA was never used in the form of a pharmaceutical composition for the therapy of pathological states related to disturbances of the nervous stimulus in the central (CNS) and peripheral (PNS) nervous system.
  • CMP-NANA is an extremely valuable compound for the treatment of disturbances of the nervous stimulus in the central (CNS) or peripheral (PNS) nervous system, for example: alterations of the nervous transmissions at the CNS or PNS level, traumatic and toxic damages of the peripheric nerves, disturbances of the memory in the consequence of pathological events as the Huntington's Corea, senile dementia, confusional states of artheriosclerotic or vascular origin, optical retrobulbar neurites, paralysis of the oculomotoric nerves, neuralgias of trigeminus, paralysis of the facial or the Bell's nerve, Garcin's syndrome, Guillan Barre's syndrome, radiolites, di.abetical and alcoholical polyneurites, obstetrical paralysis, motoneuronical diseases, lateral amiotrofic sclerosis, myelopatic muscular atrophy, progressive bulbar paralysis, serious miastenia, muscular distrophy, disturbances of the conscience as the
  • CMP-NANA (I) can be obtained by two new enzymatic methods, both of which are based on the condensation of cytidine triphosphate (CTP) with N-acetylneuraminic acid (NANA) catalyzed by the enzyme CMP-acylneuraminate synthase ( EC 2.7.7A3).
  • the condensation of CTP with NANA is catalyzed by the enzyme CMP-acylneuraminate synthase (EC 2.7.7.43), either cell-free, soluble or immobilized on a suitable solid carrier from various natural sources in the presence of BrCN, which allows chemical bonding between proteinic structure of enzyme and sol-id support, a thiocarboxylic acid stabilizer and/or a nitroimidazole stabilizer.
  • CMP-acylneuraminate synthase EC 2.7.7.43
  • suitable solid carrier from various natural sources in the presence of BrCN, which allows chemical bonding between proteinic structure of enzyme and sol-id support, a thiocarboxylic acid stabilizer and/or a nitroimidazole stabilizer.
  • the second method (B) can also optionally be accomplished in the presence of a thiocarboxylic acid stabilizer and/or nitro-imidazole stabilizer and/or under the conditions of method (A).
  • one object of the invention is a pharmaceutical composition for use in the therapy of pathological states related to disturbances of the nervous stimulus in the central (CNS) and peripheral (PNS) nervous system comprising the cytidine monophosphate of 5-acetamido-3,5-dideoxy-D-glycero-D-galactononulosaminic acid (I).
  • Another object of the invention is a method for preparing (I), by the condensation of cytidine triphosphate (CTP) with N-acetyl- neuraminic acid (NANA) catalyzed by the enzyme CMP-acylneuraminate synthase (EC 2.7.7.43) characterized in that (A) the condensation is accomplished in the presence of a thiocarboxylic acid stabilizer and/or a nitro-imidazole stabilizer or (B) that the condensation is accomplished by the enzyme CMP-acylneuraminate synthase (EC 2.7.7.43) isolated by the E. coli strain CRC 1482.
  • CTP cytidine triphosphate
  • NANA N-acetyl- neuraminic acid
  • CMP-acylneuraminate synthase EC 2.7.7.43
  • the invention avoids most of the problems related to the therapeutic usage of gangliosides, besides it allows following advantages:
  • the preferred millimolar ratio CTP/NANA is from 3.0 - 5.0 : 1.0 mmol.
  • the preferred pH is between 8.5 and 8.8.
  • the condensation is accomplished at a temperature from 30 - 40°C and preferably from 1 to 4 hours.
  • the thiocarboxylic acid and nitroimidazole stabilizers are used in an amount from 0.5 - 2.0 m M per mMol of CTP or per liter of total volume.
  • thiocarboxylic acid stabilizer the most different thiocarboxylic acids or mercaptocarboxylic acids can be used, for example acids of the formula HS(CH2)nCOOH, wherein n represents an integer from 1 to 5, like mercaptoacetic acid or ß-thiopropionic acid or acids of the given formula, in which a methylene group -CH Z - is substituted by an alkyl group, for example (+)-ß-thio- ⁇ -methyl- propionic acid and (+)-B-thio-a-ethylpropionic acid.
  • acids of the formula HS(CH2)nCOOH wherein n represents an integer from 1 to 5, like mercaptoacetic acid or ß-thiopropionic acid or acids of the given formula, in which a methylene group -CH Z - is substituted by an alkyl group, for example (+)-ß-thio- ⁇ -methyl- propionic acid and (+)-B-thio-a-ethy
  • nitro-imidazole stabilizer the most different nitro-imidazoles and nitro-imidazole derivatives can be used for example those of the following formula: wherein the nitro group may be in the 2-, 4- or 5-position and R represents hydrogen or an optionally substituted alkyl group, for example an hydroxyethyl or ß-ethylthioethyl group.
  • Typical useful nitro-imidazoles are: 2-nitro-imidazole; 2-methyl-5-nitro-1-hydroxyethylimidazole and 2-methyl-5-nitro-1-ß-ethylthioethyl- imidazole.
  • the thiocarboxylic acids act as antioxidants. Because of their high hydrophilicity and buffering properties they are preferred over similar compounds like alkylthiols.
  • nitroimidazols are especially advantageous because of their bacteriostatic activity.
  • reaction product (I) is isolated by ion exchange chromatography, and/or by chromatography on Sephadex columns using linear gradient of buffers that have pH between 8.2 - 8.6 as e.g. triethylamine/sodium bicarbonate, or aqueous ammonia 0.5-1.5 mM solution, and working at 0 - 6 0 C.
  • buffers that have pH between 8.2 - 8.6 as e.g. triethylamine/sodium bicarbonate, or aqueous ammonia 0.5-1.5 mM solution, and working at 0 - 6 0 C.
  • the enzyme CMP-acylneuraminate synthase (EC 2.7.7.43), for which also the name CMP-transferase is used, can be used either cell-free, soluble or immobilized on a suitable solid carrier, or present in the bacterial cell of the strain Escherichia coli CRC-1482
  • the cell-free enzyme can be isolated according to known isolation procedures as described for example by F.A. Troy et al., J. Biol. Chem. 249 (1974) 156; I.K. Vijay, J. Biol. Chem. 250 (1975) 164; J. Haverkamp et al., Hoppe - Seyler's Z. Physiol. Chem.
  • ß-thiopropionic acid or (+)-ß-thio- ⁇ -ethylpropionic acid in a concentration from 0.5 to 2.0 m M per liter of total volume maintaining the pH between 7.1 - 7.2 and at temperatures between 0 - 4 0 C, while in the cases where immobilized enzyme EC 2.7.7.43 is used, its immobilization is performed for example by binding on the suitable solid carrier, as for example Sepharose.
  • the immobilization is accomplished in the presence of appropiate stabilizers at a pH from 8.5 to 9.0.
  • Useful stabilizers are for example bromocyanide (CNBr) as well as the most different thiocarboxylic acid stabilizers and nitroimidazoles and nitroimidazole derivatives, already mentioned above as additives for the CTP-NANA-condensation reaction.
  • the nitroimidazoles and derivatives thereof function as anti-oxydation stabilizers as well as bactericides
  • Frog liver (200g, from Rana Esculenta) was homogenized in an Ultra-Turrax homogenizer at 90s using equal volume of 80mM Tris/HCl buffer, pH 7.2, containing 1 mM of ß-thio-propionic acid, and under cooling in an ice bath.
  • the homogenate was centrifuged (90000 x g, 30 min.), supernatant collected and centrifuged for another 60 min. at 90000 x g.
  • the second supernatant (ca. 250 ml) was applied on a DEAE-Sephadex A-50 column previously equilibrated with 80mM Tris/HCl buffer of a pH 7.2, containing 1 mM of ß-thio-propionic acid.
  • the suspension was centrifuged at 9500 x g, the precipitate was washed (2 x Tris buffer, pH 7.2, 2 x 0.01M phosphate buffer, pH 7.6), and the enzyme was finally eluated from the gel by washing with O.lM phosphate buffer of a pH 7.8.
  • the enzyme extract (5ml, containing 5-6 units/ml) was diluted with 100mM bicarbonate, pH 8.2, (1:2), and mixed at 0°C with the slurry of Sepharose 4B, activated with cyanogen bromide (according to A.P. Corfield et al., Biochem. J. 177, 1 (1979)). After shaking for 12 hours at 4 0 C, the gel was filtered, washed with water and 2N sodium chloride, and again with water.
  • the gel was stored at 0-6°C in 80mM Tris)HCl, containing 0.6 mM of ( ⁇ )ß-thio- ⁇ -methyl-propionic acid, and 2mM of 2-nitroimidazole as bactericide.
  • the immobilized enzyme thus prepared (100 units) was used for the catalytic preparation of I.
  • the incubation was performed in a Biogen continuous culture apparatus (American Sterilizer), the pH was controlled by the automatic addition of 2% sodium hydroxide, while N-acetylneuraminic acid was added in small portions during the first two hours. After completion of the reaction the gel was filtered off, and washed with water. The collected washings were applied to the DOWEX 1 x 8 column, bicarbonate form. Using a linear gradient 0 - 1.5M triethylamine/NaHCO 3 buffer, pH 8.4, at the flow rate 0.6 ml/min, the compound I (88%) was eluated. Pure I was separated from contaminating CMP by the second chromatography on a column of Sephadex G-25, eluated with 1 mM aqueous ammonia, freeze-dried, and stored at -10°C. The yield was 58%.
  • An Escherichia coli strain has been developed by repeated selection of the cultures with maximal CMP-acylneuraminate synthase activity.
  • the cultures were grown on a medium of the following composition (per liter of the total volume): 15g agar, 6g yeast extract, 2g glycine, 4g dextrose, 0.2g ß-thiopropionic acid, 4g disodium hydrogen phosphate, 2g monosodium dihydrogen phosphate and 0.2g trimethylbenzyl ammonium hydroxide. All ingredients were previously dissolved in 20-50ml of water and sterilized separately. Small scale experiments were performed on a rotary shaker (new Brunswich) at 240rpm.
  • the study has been performed with 16 couples of the rats Charles River in their reproductive age, selected by uniform weight. On the third day of gestation they have been arbitrarily divided into 4 groups. The two first groups have been fed with a semisynthetic diet that contained 10% of casein. Dietetic treatment have been continued during the entire periods of gestation and nursing.
  • Table 1 demonstrates that in the group of the rats fed with normal proteinic diet, as well as in the group treated with a hypo- proteinic diet, the treatment with CMP-NANA has inhanced in statistically significant manner, both the explorative activity as well as the NANA content in the cerebral gangliosides and glycoproteins.
  • the first group has been classified as the control group, the second group has been treated with physiological solution, the third group has been treated with kainic acid and the fourth group has been treated with CMP-NANA (20mg/kg/day, i.p.) and kainic acid.
  • the treatment with CMP-NANA has been started one week before the treatment with kainic acid and has been continued until the animals have been sacrified.
  • the animals have been anesthetized with pentobarbital (60mg/kg i.p.) and then treated with kainic acid (2pg in 1 ⁇ l of the physiological solution), that has been injected into striatum.
  • control rats have been treated with an equal volume (1 ⁇ l) of the physiological solution.
  • the rats After 7 days the rats have been sacrified and the striatum has been removed. Each single determination has been performed with the pool of 5 samples. The gangliosides have been extracted and determined (as NANA content) as described previously.
  • Table 2 illustrates the results, showing that the treatment with CMP-NANA has hindered the diminuation of the level of gangliosides in the striatum determined by kainic acid.
  • CMP-NANA [9 - 3 H] has been purchased from NEN (New England Nuclear, 6072 Dreieich, West Germany).
  • the measurements have been quantized using a canal to canal-ratio technique. Table 3 illustrates the averaged results of all measurements. The radioactivity was rapidly diminished in the blood, and more slowly in the organs. The brain has demonstrated a radioactivity level inferior to those of the liver and kidney.
  • Neuro-2a cells (American Type Culture Collection, Rockville, USA) were seeded at standard conditions (10 4 - 10 6 cells/100mm dish). After 12 - 24 hours CMP-NANA was added, with the concentrations indicated in Table 4. Incubation time for quantification of sprouting was 24 hours. Thereafter fixation of the cells was performed by means of 3% glutaraldehyde containing buffered saline. Quantitative determination of nerve cell growth was performed with Zeiss D-7082 Micreo-Videomat.
  • Neurite sprouting was used as the parameter for nerve cell differentiation.
  • the samples fixed in formaline were stained for better contrast.
  • a close dose-response relationship has been observed between the amount of CMP-NANA added and the number of neurites protruding from the cells (Table 4).
  • Neuro-2a neurine neuroblastoma (American Type Culture Collection - CCL 131) was grown in the medium consisting of fecal calf serum (Irvine Scientific, Irvine, Ca.), to which non-essential amino acids, antibiotic (5 - 20mg %), and bicarbonate (50 - 100 mg %), were added. The cells were grown routinely on corning plastic tissue- culture flasks.
  • Cells for assay were plated on corning plastic Petri dishes, in the medium with or without CMP-NANA.
  • CMP-NANA In order to examine the role of CMP-NANA on in vitro neuron maturation, it was incorporated into the culture media at the time of plating or 24 or 48 hours post- plating. The mean number and length of cell processes were repeatedly determined for a minimum of 100 cells per treatment group, to provide a semiquantitative index of neuron maturation (Table 5).
  • I.M. L.P. x N.P.
  • Active ingredient, mannitol and the inorganic salts were dissolved in sterile water for injections, the final pH being 6.5-6.7.
  • the solution is sparged with steril nitrogen and is then clarified by filtration through a membrane filter of the pore size 0.45 ⁇ , then it is packed into glass ampoules of 2 ml.
  • Liofilization was performed in an adequate liofilisator maintaining the freezing temperature between -58°C and -60°C, and by the final heating up to 35°C.
  • the ampoules thus obtained are sealed under sterile nitrogen.
  • the product was controlled by physico-chemical properties, residual humidity,the CMP-NANA content, redissolution, sterility, absence of pyrogenic materials, and non-toxicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP84102059A 1983-03-01 1984-02-28 Pharmazeutische Zusammensetzung welche 5-Acetamido-3,5-Dideoxy-D-Glycero-D-Galactononulosaminsäure Cytidin Monophosphat enthält Expired EP0120328B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT84102059T ATE37984T1 (de) 1983-03-01 1984-02-28 Pharmazeutische zusammensetzung welche 5acetamido-3,5-dideoxy-d-glycero-dgalactononulosamins|ure cytidin monophosphat enthaelt.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT8334183 1983-03-01
IT83341/83A IT1175061B (it) 1983-03-01 1983-03-01 Applicazione terapeutica del citidin monofosfato dell'acido 5-acetamido-3,5-dideossi-d-glicero-d-galattononulo saminico
IT83371/83A IT1175084B (it) 1983-04-20 1983-04-20 Metodo per la preparazione del citidin monofosfato dell'acido 5-acetamido-3,5-dideossi-d-glicero-d-galattononulo-saminico
IT8337183 1983-04-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP87114882A Division EP0263533A3 (de) 1983-03-01 1984-02-28 Verfahren zur Herstellung von Cytidinmonophosphat von 5-Acetamido-3,5-dideoxy-D-glycero-D-galactononulosaminsaeure
EP87114882.1 Division-Into 1984-02-28

Publications (3)

Publication Number Publication Date
EP0120328A2 true EP0120328A2 (de) 1984-10-03
EP0120328A3 EP0120328A3 (en) 1985-01-23
EP0120328B1 EP0120328B1 (de) 1988-10-19

Family

ID=26330056

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87114882A Withdrawn EP0263533A3 (de) 1983-03-01 1984-02-28 Verfahren zur Herstellung von Cytidinmonophosphat von 5-Acetamido-3,5-dideoxy-D-glycero-D-galactononulosaminsaeure
EP84102059A Expired EP0120328B1 (de) 1983-03-01 1984-02-28 Pharmazeutische Zusammensetzung welche 5-Acetamido-3,5-Dideoxy-D-Glycero-D-Galactononulosaminsäure Cytidin Monophosphat enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP87114882A Withdrawn EP0263533A3 (de) 1983-03-01 1984-02-28 Verfahren zur Herstellung von Cytidinmonophosphat von 5-Acetamido-3,5-dideoxy-D-glycero-D-galactononulosaminsaeure

Country Status (6)

Country Link
US (2) US4704361A (de)
EP (2) EP0263533A3 (de)
JP (1) JPH0276894A (de)
AT (1) ATE37984T1 (de)
CA (1) CA1219539A (de)
DE (1) DE3474632D1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194563A3 (de) * 1985-03-06 1988-06-01 MECT Corporation Glycoside und Verfahren zu ihrer Herstellung
EP0408668A4 (en) * 1988-10-27 1991-11-27 Massachusetts Institute Of Technology Process for increasing phosphatidylcholine in vivo
EP0524143A1 (de) * 1991-07-17 1993-01-20 Ciba-Geigy Ag Verfahren zur Herstellung aktivierter Sialinsäuren
EP0765666A1 (de) * 1995-08-31 1997-04-02 Research Development Corporation Of Japan Hemmung der unregelmässigen Linsen-Zellbindungen

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109126A (en) * 1988-12-06 1992-04-28 Worcester Foundation For Experimental Biology 5'[2'(3')-O-(2,4,6-trinitrophenyl) pyprimidine nucleoside]diphosphate 1-glycosides
US5059535A (en) * 1989-04-12 1991-10-22 Chembiomed, Ltd. Process for the separation and purification of sialyl transferases
FI941732L (fi) * 1991-10-15 1994-06-14 Scripps Research Inst Fukosyloitujen hiilihydraattien valmistaminen sokerinukleotidien entsymaattisella fukosylointisyteesillä ja GDP-fukoosin in situ regenerointi
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
BR0316054A (pt) * 2002-11-08 2005-09-20 Mclean Hospital Corp Compostos para tratamento de dependência e privação de tabaco
US20050038343A1 (en) * 2003-07-10 2005-02-17 Alfred E. Mann Institute For Biomedical Research At The University Of Southern California Apparatus and method for locating a bifurcation in an artery
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
EP1765075A4 (de) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP2049144B8 (de) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (en) * 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
DE2648759C3 (de) * 1976-10-27 1979-05-31 Boehringer Mannheim Gmbh, 6800 Mannheim Stabilisierungsmittel für Enzyme
US4593091A (en) * 1981-08-04 1986-06-03 Fidia, S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Tenth Collective Index, vol. 86-95, 1977-1981, Chemical Substances, "2-Naphthalenol - Norleucinamide", The American Chemical Society * Page 35040CS, D-glycero-SS-D-galacto-2-Nonulopyranosonic acid; 2-(hydrogen 5'-cytidylate) (3063-71-6) * *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194563A3 (de) * 1985-03-06 1988-06-01 MECT Corporation Glycoside und Verfahren zu ihrer Herstellung
EP0408668A4 (en) * 1988-10-27 1991-11-27 Massachusetts Institute Of Technology Process for increasing phosphatidylcholine in vivo
EP0524143A1 (de) * 1991-07-17 1993-01-20 Ciba-Geigy Ag Verfahren zur Herstellung aktivierter Sialinsäuren
US5334514A (en) * 1991-07-17 1994-08-02 Matthias Kittelmann Process for the production of activated sialic acids
SG49879A1 (en) * 1991-07-17 2001-03-20 Forschungszentrum Juelich Gmbh A process for the preparation of activated sialic acids
EP0765666A1 (de) * 1995-08-31 1997-04-02 Research Development Corporation Of Japan Hemmung der unregelmässigen Linsen-Zellbindungen

Also Published As

Publication number Publication date
JPH0276894A (ja) 1990-03-16
EP0263533A2 (de) 1988-04-13
EP0263533A3 (de) 1990-05-30
CA1219539A (en) 1987-03-24
US5070079A (en) 1991-12-03
EP0120328A3 (en) 1985-01-23
EP0120328B1 (de) 1988-10-19
ATE37984T1 (de) 1988-11-15
US4704361A (en) 1987-11-03
DE3474632D1 (en) 1988-11-24

Similar Documents

Publication Publication Date Title
EP0120328B1 (de) Pharmazeutische Zusammensetzung welche 5-Acetamido-3,5-Dideoxy-D-Glycero-D-Galactononulosaminsäure Cytidin Monophosphat enthält
US4329302A (en) Synthetic phosphoglycerides possessing platelet activating properties
US4476119A (en) Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
EP0125039A2 (de) Verfahren zur Herstellung von Phospholipid-Saccharid-Derivaten
EP0354246A1 (de) 3'-Azido-2',3'-dideoxynucleosid-5'-phosphonate
US5441932A (en) Sugar compounds for inhibition of the biosynthesis of sugar chains containing sialic acid
CA1243971A (en) Method for producing cytidine monophosphate of 5- acetamido-3,5-dideoxy-d-glycero-d- galactononulosaminic acid
EP0524143B1 (de) Verfahren zur Herstellung aktivierter Sialinsäuren
US4822879A (en) Enzyme-inhibitory griseolic acid derivatives, and their use
EP0395106B1 (de) Demethylallosamidin und ein Verfahren zu seiner Herstellung
US5296360A (en) Process for producing ganglioside GM1
DE3626915A1 (de) Verfahren zur enzymatischen synthese eines n-acetylneuraminsaeure-haltigen trisaccharids
JPH0216732B2 (de)
US5585512A (en) Esters of p-hydroxyaniline mustard
US4990500A (en) Oxirane pseudooligosaccharides, a process for their preparation, their use and pharmaceutical preparations
DE69720101T2 (de) Makrolid Verbindung 0406
SU1482946A1 (ru) Способ получени копропорфирина Ш
US4504474A (en) Synthetic phosphoglycerides possessing platelet activating properties
US5409912A (en) Leustroducsin H, its preparation and its therapeutic use
JPH0630611B2 (ja) 細胞分化誘導物質
US4551446A (en) Use of synthetic phosphoglycerides possessing platelet activating properties as desensitizing agents
JP2971204B2 (ja) 新規物質ｗｋ−２９５５およびその製造法
JP4336400B2 (ja) 酵素誘導剤及びそれを用いる酵素製造方法
JPH02268118A (ja) 免疫賦活剤
Yoo et al. Effect of glucocorticoids on the production of lactate dehydrogenase, malate dehydrogenase and alpha-fetoprotein by Morris hepatoma 7777 in vitro

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17P Request for examination filed

Effective date: 19850712

17Q First examination report despatched

Effective date: 19870416

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19881019

REF Corresponds to:

Ref document number: 37984

Country of ref document: AT

Date of ref document: 19881115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3474632

Country of ref document: DE

Date of ref document: 19881124

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19910111

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19910122

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19910125

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19910220

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19910228

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19910304

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19910422

Year of fee payment: 8

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19920228

Ref country code: GB

Effective date: 19920228

Ref country code: BE

Effective date: 19920228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19920229

Ref country code: CH

Effective date: 19920229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19920301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920311

Year of fee payment: 9

BERE Be: lapsed

Owner name: CRC COMPAGNIA DI RICERCA CHIMICA S.P.A.

Effective date: 19920228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19920901

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19921030

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19931103

EUG Se: european patent has lapsed

Ref document number: 84102059.7

Effective date: 19921005